In line with our findings, EP300 inhibition has demonstrated efficacy in reversing hemodynamic abnormalities and pulmonary vascular remodeling in experimental PAH (Chelladurai et al. 2022). This evidence concerns the gene EP300 and pulmonary arterial hypertension.